Who Optimizes SG&A Costs Better? GSK plc or Celldex Therapeutics, Inc.

SG&A Cost Optimization: GSK vs. Celldex

__timestampCelldex Therapeutics, Inc.GSK plc
Wednesday, January 1, 2014206220008246000000
Thursday, January 1, 2015338370009232000000
Friday, January 1, 2016359790009366000000
Sunday, January 1, 2017250030009672000000
Monday, January 1, 2018192690009915000000
Tuesday, January 1, 20191542600011402000000
Wednesday, January 1, 20201445600011456000000
Friday, January 1, 20212048800010975000000
Saturday, January 1, 2022271950008372000000
Sunday, January 1, 2023309140009385000000
Loading chart...

Unlocking the unknown

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, GSK plc and Celldex Therapeutics, Inc. have taken different paths in optimizing these costs.

A Decade of Financial Strategy

From 2014 to 2023, GSK plc consistently maintained high SG&A expenses, peaking at approximately $11.5 billion in 2020. Despite this, GSK's expenses showed a slight downward trend, decreasing by about 18% by 2022. In contrast, Celldex Therapeutics, Inc. exhibited a more volatile pattern, with expenses fluctuating between $14 million and $36 million. Notably, Celldex's SG&A costs surged by 50% from 2020 to 2023, indicating a strategic shift or expansion.

Conclusion

While GSK's large-scale operations justify its higher expenses, Celldex's recent increase suggests a potential growth phase. Understanding these trends offers valuable insights into each company's strategic priorities.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025